RxDoctor Payments Data

Amanda Brooks, NP

Nurse Practitioner · Macon, GANPI 1902443039

Payments from drug & device makers

$2,559in general payments, 2019–2025

Across 105 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$421
  • AbbVie$414
  • Novo Nordisk$179
  • Lilly USA, LLC$158
  • Phathom Pharmaceuticals, Inc.$141
  • Amgen$136
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,559100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,559 in reported general payments places this provider in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$33,321
Medicare patients
138
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide23$27,712
OzempicSemaglutide15$17,874
FarxigaDapagliflozin Propanediol15$11,377
JardianceEmpagliflozin14$10,241
Repatha SureclickEvolocumab11$6,996
Doxepin Hcl12$3,054
Rosuvastatin Calcium36$1,017
Levothyroxine Sodium39$747
Azelastine Hcl16$672
Famotidine36$595
Ezetimibe24$538
Fluticasone Propionate22$454
Pantoprazole Sodium34$361
Olmesartan Medoxomil28$315
Metoprolol Succinate18$312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$158$27,71223 claims
Novo NordiskOzempic$179$17,87415 claims
AstraZenecaFarxiga$421$11,37715 claims
Boehringer IngelheimJardiance$50$10,24114 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$38$74739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →